Aleixo Santiago
About Aleixo Santiago
Aleixo Santiago is a director at Abeona Therapeutics Inc., where he has worked since 2018. He has extensive experience in the pharmaceutical industry, having held various roles at companies such as Regeneron Pharmaceuticals and Sanofi, and he holds a doctorate from the University of Florida.
Current Role at Abeona Therapeutics
Aleixo Santiago serves as the Director at Abeona Therapeutics Inc. since 2018. His role involves overseeing various projects and initiatives within the organization, which focuses on developing gene and cell therapies for severe diseases. Located in Cleveland, Ohio, Abeona Therapeutics is known for its commitment to advancing innovative treatments.
Previous Experience at Regeneron Pharmaceuticals
Aleixo Santiago worked at Regeneron Pharmaceuticals, Inc. in two capacities. He was a Scientist from 2011 to 2013, contributing to research and development efforts in Albany, New York. Following this, he served as a Senior Scientist from 2013 to 2014, furthering his expertise in the pharmaceutical field during this period.
Educational Background
Aleixo Santiago holds a Bachelor of Science degree from North Dakota State University, where he studied from 1997 to 2001. He furthered his education at Penn State University, earning a Master of Science degree from 2002 to 2003. Additionally, he obtained a Doctor of Philosophy degree from the University of Florida, completing his studies from 2004 to 2008.
Work History in the Pharmaceutical Industry
Aleixo Santiago has extensive experience in the pharmaceutical industry. He began his career as a Research and Teaching Assistant at North Dakota State University from 1999 to 2002. He later held positions at Centocor as a Pharmaceutical Development Coop in 2004, Johnson & Johnson as a Postdoctoral Research Fellow from 2009 to 2011, and Sanofi as Deputy Director Principal Scientist from 2014 to 2018.
Early Career Experience
In the early stages of his career, Aleixo Santiago gained valuable experience through various internships and cooperative positions. He worked at GSK as a Safety Assessment Coop for six months in 2003 and at Centocor for seven months in 2004. These roles provided foundational knowledge in safety assessment and pharmaceutical development.